Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study

326 Riedl, M.*+, Farkas, H.*, Bernstein, J. A., Bouillet, L., Sheridan, W. P., and Maurer, M.: Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy 2018: 73; 1871-1880. IF: 6.77